Quarterly report pursuant to Section 13 or 15(d)

Schedule of Accrued Expenses (Details)

v3.21.1
Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Payroll and incentives $ 303 $ 1,094
General and administrative expenses 234 280
Research and development expenses 683 778
Deferred revenue and other deferred liabilities * [1] 186 643
Total $ 1,406 $ 2,795
[1] At December 31, 2020, approximately $577 thousand is the remaining balance of the CFF Agreement’s deferred liability and approximately $67 thousand is deferred revenue related to the Genentech Agreement. At March 31, 2021, approximately $153 thousand is the remaining balance of the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech Agreement. (See Note 9 – Collaboration Agreements, Licenses and Other Research and Development Agreements).